{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:40:45Z","timestamp":1791463245302,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The importance or necessity of a loading dose when prescribing intravenous colistin has not been well established in clinical practice, and approximate one-third to half of patients with carbapenem-resistant gram-negative bacteria (CRGNB) infection did not receive the administration of a loading dose. The aim of this study is to investigate the efficacy and risk of acute kidney injury when prescribing intravenous colistin for critically ill patients with nosocomial pneumonia caused by CRGNB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a multicenter, retrospective study that recruited ICU-admitted patients who had CRGNB-associated nosocomial pneumonia and were treated with intravenous colistin. Then, we classified the patients into colistin loading dose (<jats:italic>N<\/jats:italic>\u2009=\u200985) and nonloading dose groups (<jats:italic>N<\/jats:italic>\u2009=\u2009127). After propensity-score matching for important covariates, we compared the mortality rate, clinical outcome and microbiological eradication rates between the groups (<jats:italic>N<\/jats:italic>\u2009=\u200967).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The loading group had higher percentages of patients with favorable clinical outcomes (55.2% and 35.8%, <jats:italic>p<\/jats:italic>\u2009=\u20090.037) and microbiological eradication rates (50% and 27.3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.042) at day 14 than the nonloading group. The mortality rates at days 7, 14 and 28 and overall in-hospital mortality were not different between the two groups, but the Kaplan\u2013Meier analysis showed that the loading group had a longer survival time than the nonloading group. Furthermore, the loading group had a shorter length of hospital stay than the nonloading group (52 and 60, <jats:italic>p<\/jats:italic>\u2009=\u20090.037). Regarding nephrotoxicity, there was no significant difference in the risk of developing acute kidney injury between the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The administration of a loading dose is recommended when prescribing intravenous colistin for critically ill patients with nosocomial pneumonia caused by CRGNB.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-03947-9","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:04:08Z","timestamp":1649073848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study"],"prefix":"10.1186","volume":"26","author":[{"given":"Sheng-Huei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau-Chyun","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Cheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yih","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biing-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Rong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-2557","authenticated-orcid":false,"given":"Chung-Kan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the T.-CARE (Taiwan Critical Care, Infection) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"issue":"3","key":"3947_CR1","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)\/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociaci\u00f3n Latinoamericana del T\u00f3rax (ALAT). Eur Respir J. 2017;50(3):1700582.","journal-title":"Eur Respir J"},{"issue":"4","key":"3947_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","volume":"171","author":"American Thoracic Society","year":"2005","unstructured":"American Thoracic Society. Infectious Diseases Society of America: guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3947_CR3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/cid\/ciy543","volume":"68","author":"A Bonell","year":"2019","unstructured":"Bonell A, Azarrafiy R, Huong VTL, Viet TL, Phu VD, Dat VQ, Wertheim H, van Doorn HR, Lewycka S, Nadjm B. A systematic review and meta-analysis of ventilator-associated pneumonia in adults in Asia: an analysis of national income level on incidence and etiology. Clin Infect Dis. 2019;68(3):511\u20138.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3947_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cmi.2018.01.015","volume":"24","author":"L Papst","year":"2018","unstructured":"Papst L, Beovi\u0107 B, Pulcini C, Durante-Mangoni E, Rodr\u00edguez-Ba\u00f1o J, Kaye KS, Daikos GL, Raka L, Paul M. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clin Microbiol Infect. 2018;24(10):1070\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"3947_CR5","first-page":"1815","volume":"67","author":"Y Zak-Doron","year":"2018","unstructured":"Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, et al. The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant gram-negative bacteria: a prospective study. Clin Infect Dis. 2018;67(12):1815\u201323.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3947_CR6","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1128\/AAC.00035-06","volume":"50","author":"PJ Bergen","year":"2006","unstructured":"Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3947_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijantimicag.2004.10.001","volume":"25","author":"J Li","year":"2005","unstructured":"Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25(1):11\u201325.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"3947_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1592\/phco.30.12.1279","volume":"30","author":"LM Lim","year":"2010","unstructured":"Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A 3rd, Forrest A, Bulitta JB, Tsuji BT. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279\u201391.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"3947_CR9","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.01733-10","volume":"55","author":"SM Garonzik","year":"2011","unstructured":"Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284\u201394.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"3947_CR10","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.1128\/AAC.00554-15","volume":"59","author":"I Karaiskos","year":"2015","unstructured":"Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, Kostakou E, Baziaka F, Paskalis C, Koutsoukou A, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically Ill patients. Antimicrob Agents Chemother. 2015;59(12):7240\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3947_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/AAC.02634-15","volume":"60","author":"MH Rigatto","year":"2016","unstructured":"Rigatto MH, Oliveira MS, Perdig\u00e3o-Neto LV, Levin AS, Carrilho CM, Tanita MT, Tuon FF, Cardoso DE, Lopes NT, Falci DR, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3947_CR12","doi-asserted-by":"publisher","first-page":"e02316","DOI":"10.1128\/AAC.02329-16","volume":"61","author":"RL Crass","year":"2017","unstructured":"Crass RL, Rutter WC, Burgess DR, Martin CA, Burgess DS. Nephrotoxicity in patients with or without cystic fibrosis treated with polymyxin B compared to colistin. Antimicrob Agents Chemother. 2017;61(4):e02316\u201329.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3947_CR13","doi-asserted-by":"publisher","first-page":"e0173286","DOI":"10.1371\/journal.pone.0173286","volume":"12","author":"RK Shields","year":"2017","unstructured":"Shields RK, Anand R, Clarke LG, Paronish JA, Weirich M, Perone H, Kieserman J, Freedy H, Andrzejewski C, Bonilla H. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLOS ONE. 2017;12(3):e0173286.","journal-title":"PLOS ONE"},{"key":"3947_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/IDR.S144314","volume":"10","author":"W Katip","year":"2017","unstructured":"Katip W, Uitrakul S, Oberdorfer P. Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients. Infect Drug Resist. 2017;10:293\u20138.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"3947_CR15","first-page":"311","volume":"25","author":"E Alp","year":"2017","unstructured":"Alp E, Eren E, Elay G, Cevahir F, Esmao\u011flu A, Rello J. Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia. Infez Med. 2017;25(4):311\u20139.","journal-title":"Infez Med"},{"issue":"1","key":"3947_CR16","doi-asserted-by":"publisher","first-page":"8781","DOI":"10.1038\/s41598-019-44965-y","volume":"9","author":"S Jung","year":"2019","unstructured":"Jung S, Chung EK, Jun MS, Son ES, Rhie SJ. Differences in colistin administration and bacterial and treatment outcomes in critically Ill patients. Sci Rep. 2019;9(1):8781.","journal-title":"Sci Rep"},{"key":"3947_CR17","doi-asserted-by":"publisher","first-page":"175346661988552","DOI":"10.1177\/1753466619885529","volume":"13","author":"J Choe","year":"2019","unstructured":"Choe J, Sohn YM, Jeong SH, Park HJ, Na SJ, Huh K, Suh GY, Jeon K. Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria. Ther Adv Respir Dis. 2019;13:1753466619885529.","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"3947_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H, Karaiskos I, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339.","journal-title":"Pharmacotherapy"},{"key":"3947_CR19","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.cmi.2021.01.020","volume":"27","author":"JY Feng","year":"2021","unstructured":"Feng JY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, Chen CM, Shen YC, Zheng ZR, Lin YT, et al. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant gram-negative bacterial pneumonia: a multi-centre observational study. Clin Microbiol Infect. 2021;27:1465\u201373.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"3947_CR20","first-page":"1081","volume":"10","author":"SH Wang","year":"2021","unstructured":"Wang SH, Yang KY, Sheu CC, Chen WC, Chan MC, Feng JY, Chen CM, Wu BR, Zheng ZR, Chou YC, et al. Efficacies of colistin-carbapenem versus colistin-tigecycline in critically Ill patients with CR-GNB-associated pneumonia: a multicenter observational study. Antibiot Basel Switzerland. 2021;10(9):1081.","journal-title":"Antibiot Basel Switzerland"},{"issue":"5","key":"3947_CR21","first-page":"565","volume":"64","author":"RL Nation","year":"2017","unstructured":"Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, Li J, Silveira FP. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64(5):565\u201371.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"3947_CR22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/cid\/civ964","volume":"62","author":"RL Nation","year":"2015","unstructured":"Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Turnidge JD, Forrest A, Silveira FP. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis. 2015;62(5):552\u20138.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3947_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/ki.2014.328","volume":"87","author":"ME Thomas","year":"2015","unstructured":"Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, Latchem S, Lewington A, Milford DV, Ostermann M. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87(1):62\u201373.","journal-title":"Kidney Int"},{"issue":"11\u201312","key":"3947_CR24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1177\/0885066617725694","volume":"34","author":"W Katip","year":"2019","unstructured":"Katip W, Meechoui M, Thawornwittayakom P, Chinwong D, Oberdorfer P. Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study. J Intensive Care Med. 2019;34(11\u201312):996\u20131002.","journal-title":"J Intensive Care Med"},{"issue":"7","key":"3947_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1093\/jac\/dkaa064","volume":"75","author":"I Bellos","year":"2020","unstructured":"Bellos I, Pergialiotis V, Frountzas M, Kontzoglou K, Daskalakis G, Perrea DN. Efficacy and safety of colistin loading dose: a meta-analysis. J Antimicrob Chemother. 2020;75(7):1689\u201398.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3947_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijantimicag.2016.08.020","volume":"48","author":"JP Horcajada","year":"2016","unstructured":"Horcajada JP, Sorl\u00ed L, Luque S, Benito N, Segura C, Campillo N, Montero M, Esteve E, Mirelis B, Pomar V, et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents. 2016;48(6):725\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"3947_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/1471-2334-13-380","volume":"13","author":"L Sorl\u00ed","year":"2013","unstructured":"Sorl\u00ed L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.","journal-title":"BMC Infect Dis"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-03947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-03947-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-03947-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:23:57Z","timestamp":1649075037000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-03947-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3947"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-03947-9","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Institutional Review Boards of all the participating hospitals (registration numbers: 2018-03-001CC, 1-107-05-054, CE18100A, CMUH107-REC3-052, and KMUHIRB-E(I)-20180141).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}